La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ProQR Therapeutics Croissance future

Future contrôle des critères 1/6

Les bénéfices de ProQR Therapeutics devraient diminuer de 4.6% par an tandis que son chiffre d'affaires annuel devrait croître de 12.6% par an. Le BPA devrait croître de de 0.8% par an. Le rendement des capitaux propres devrait être -115.2% dans 3 ans.

Informations clés

-4.6%

Taux de croissance des bénéfices

0.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	12.6%
Rendement futur des capitaux propres	-115.2%
Couverture par les analystes	Good
Dernière mise à jour	27 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01

ProQR reports Q3 results

Nov 16

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:PRQR - Estimations futures des analystes et données financières antérieures (EUR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	12	-43	-52	-67	4
12/31/2025	15	-29	-18	-32	6
12/31/2024	24	-26	N/A	-29	6
6/30/2024	16	-22	-28	-34	N/A
3/31/2024	11	-27	-32	-38	N/A
12/31/2023	7	-28	28	22	N/A
9/30/2023	5	-37	8	9	N/A
6/30/2023	4	-54	1	1	N/A
3/31/2023	4	-59	-4	-3	N/A
12/31/2022	4	-64	-69	-69	N/A
9/30/2022	4	-69	-48	-47	N/A
6/30/2022	4	-61	-40	-40	N/A
3/31/2022	3	-63	-35	-35	N/A
12/31/2021	2	-61	-26	-26	N/A
9/30/2021	2	-57	-42	-42	N/A
6/30/2021	2	-55	-44	-43	N/A
3/31/2021	1	-43	-45	-44	N/A
12/31/2020	1	-47	-48	-47	N/A
9/30/2020	1	-52	-48	-47	N/A
6/30/2020	1	-51	-47	-46	N/A
3/31/2020	2	-58	-47	-47	N/A
12/31/2019	2	-56	-45	-44	N/A
9/30/2019	3	-51	-41	-41	N/A
6/30/2019	5	-45	-37	-37	N/A
3/31/2019	6	-40	-32	-31	N/A
12/31/2018	6	-37	-29	-28	N/A
9/30/2018	4	-35	-28	-28	N/A
6/30/2018	2	-40	-32	-31	N/A
3/31/2018	1	-44	N/A	-36	N/A
12/31/2017	1	-44	N/A	-35	N/A
9/30/2017	1	-41	N/A	-34	N/A
6/30/2017	1	-41	N/A	-37	N/A
3/31/2017	1	-39	N/A	-35	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	3	-36	N/A	-34	N/A
6/30/2016	3	-33	N/A	-29	N/A
3/31/2016	3	-31	N/A	-27	N/A
12/31/2015	3	-21	N/A	-24	N/A
9/30/2015	3	-17	N/A	-22	N/A
6/30/2015	1	-14	N/A	-20	N/A
3/31/2015	1	-10	N/A	-18	N/A
12/31/2014	0	-12	N/A	-14	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-9	N/A	-7	N/A
3/31/2014	0	-5	N/A	-4	N/A
12/31/2013	0	-3	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PRQR devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: PRQR devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: PRQR devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PRQR ( 16.9% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PRQR ( 16.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: PRQR devrait être non rentable dans 3 ans.

ProQR Therapeutics Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 35%

Consensus revenue estimates increase by 28%

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

Recent updates

Consensus revenue estimates increase by 35%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Consensus revenue estimates increase by 28%

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates increase by 64%, EPS downgraded

Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €170 million.

New minor risk - Share price stability

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates decrease by 25%

Consensus EPS estimates upgraded to €0.24 loss, revenue downgraded

Price target decreased by 9.2% to US$3.82

ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Price target increased to US$3.25

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ProQR Therapeutics N.V. Appoints Jurriaan Dekkers as Chief Financial Officer

Consensus forecasts updated

ProQR Therapeutics N.V. to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Consensus revenue estimates increase by 25%

ProQR says EU regulator seeks additional trial for lead candidate

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProQR Therapeutics N.V. Appoints Rene Beukema as Member of Management Board

ProQR Therapeutics N.V., Annual General Meeting, Jun 30, 2022

Consensus estimates of losses per share improve by 11%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$3.29

Price target decreased to US$3.64

ProQR Therapeutics N.V. Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for Proqr's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$13.50

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ProQR Therapeutics N.V. Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

ProQR Therapeutics N.V. Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421A for USH2A Mediated Retinitis Pigmentosa

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Consensus forecasts updated

Phoenicis Therapeutics Inc. acquired Wings Therapeutics, Inc from ProQR Therapeutics N.V. (NasdaqGM:PRQR) and others.

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

Consensus forecasts updated

ProQR Therapeutics offers a de-risked opportunity: Stifel

Price target increased to US$24.17

ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Revenue and earnings beat expectations